Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 3/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 10/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10310545 | 0.89 | MAOA (0.36) | MAOAMAOBS1PR1CD274S1PR3 | |
| SCHEMBL10088584 | 0.82 | MAOA (0.38) | MAOAMAOBS1PR1CD274S1PR3 | |
| SCHEMBL450942 | 0.80 | MAOB (0.56) | MAOAMAOBS1PR1SRD5A1 | |
| SCHEMBL10088965 | 0.79 | S1PR1 (0.49) | MAOAMAOBS1PR1S1PR3 | |
| SCHEMBL10088766 | 0.77 | S1PR1 (0.49) | S1PR1S1PR3 | |
| SCHEMBL21300674 | 0.75 | MAOB (0.51) | MAOAMAOBS1PR1SRD5A1 | |
| SCHEMBL316466 | 0.69 | CYP26A1 (0.48) | — | |
| SCHEMBL27642474 | 0.68 | S1PR1 (0.59) | MAOAMAOBS1PR1S1PR3 | |
| SCHEMBL1874151 | 0.67 | SRD5A1 (0.55) | MAOAMAOBS1PR1SRD5A1 | |
| SCHEMBL31435344 | 0.67 | MAOB (0.44) | MAOAMAOBS1PR1SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8193378-B2 | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, CCR1 | MAOA 2123/4885MAOB 2521/4885S1PR1 1/4885 |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, S1PR4 | MAOA 2984/4885MAOB 3106/4885S1PR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.